Study shows most doctors endorsing drugs on X are paid to do so

Access to the Study and Data Sources

• Commenters share direct links to the JAMA paper and to a ResearchGate copy, noting the article does not list the specific 28 physicians analyzed.
• The U.S. Open Payments database is highlighted as a key tool for checking financial ties between physicians and industry.
• Example searches show some prominent media doctors receiving six‑figure consulting payments, while others have only small “food and beverage” entries.

Magnitude and Nature of Payments

• Related coverage cites $12.1B in payments to U.S. doctors over 2013–2022.
• Some argue the average (~$12k/doctor/year) sounds modest; others say that much is effectively “a month’s salary,” and thus a powerful incentive.
• Clarification that free drug samples are not included; reported items range from brief paid consulting to high‑paid speaking and advisory roles.

Transparency, Disclosure, and Regulation

• Debate over whether U.S. rules adequately mirror social‑media advertising standards requiring clear, in‑context sponsorship disclosure.
• Some see Open Payments as sufficient transparency; others call it a “pretend solution” because most patients don’t know it exists or won’t check it.
• There is disagreement about what is currently illegal: some assert doctors must disclose conflicts and that prescribing under undisclosed influence is unlawful; others say enforcement is weak or unclear.
• Comparisons are made to stricter advertising rules in other countries (e.g., no direct‑to‑consumer Rx ads).

Ethical Concerns and Patient Trust

• Many argue that being paid to endorse drugs is inherently in tension with a physician’s duty of loyalty to patients, especially given information asymmetry and patient vulnerability.
• Some call for revoking licenses for undisclosed endorsements and criminal penalties for company “bribery.”
• Others accept paid roles if conflicts are clearly disclosed, both publicly and to individual patients.

Influence on Prescribing and Public Messaging

• Cited evidence and discussion agree that marketing does influence physician behavior, even when framed as “education” about new approvals.
• Direct‑to‑consumer ads are criticized for prompting patients to demand specific drugs, which some fear doctors may prescribe rather than re‑fight lifestyle battles.
• A personal anecdote describes a doctor’s office saturated with a single drug’s branding and strong pressure to stay on that drug despite serious side effects, interpreted as evidence of distorted incentives.

Broader Skepticism and Health Culture

• Several comments express broad distrust of the pharmaceutical–medical complex, calling the system “corrupt” and focused on wealth extraction.
• Others distinguish between skepticism of companies and trust in specific treatments (e.g., vaccines), noting that corruption in promotion does not automatically mean a drug is ineffective.
• A side discussion explores how culture, urban design, and diet interact with heavy reliance on pharmacologic solutions, especially around obesity, with disagreement over whether lifestyle or drugs should be emphasized.